Etherified pullulan-polyethylenimine based nanoscaffolds improved chemosensitivity of erlotinib on hypoxic cancer cells.

Bera, Hriday; Abosheasha, Mohammed A.; Ito, Yoshihiro; Ueda, Mitsuru

doi:10.1016/j.carbpol.2021.118441

Cited by 8 publications

(27 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, PULL–CC–PTX) were synthesized according to the scheme illustrated in Figure A. CM–PULL was initially afforded employing the Williamson ether synthesis protocol . The hydroxyl groups of PULL chains were alkalized in the presence of sodium hydroxide to produce PULL alkoxide, which was subsequently reacted with monochloroacetic acid to obtain CM–PULL via an S N 2 -type reaction mechanism.…”

Section: Resultsmentioning

confidence: 99%

“…Figure B illustrates the FT–IR spectra of native PULL and its conjugates. In the IR spectrum of unmodified PULL, various distinct absorption signals such as OH stretching, CH 2 stretching, and glycosidic (α-(1,4) and α-(1,6)) stretching were evident at 3420, 2923, and 1104 cm –1 , respectively . CM–PULL possessed a new peak at 1640 cm –1 , which was ascribed to the symmetrical stretching vibration of the carboxylate (COO – ) group.…”

Section: Resultsmentioning

confidence: 99%

“…4 The specific P-XRD peak of native PULL became comparatively broader in the case of prodrug NPs, implying that the intramolecular hydrogen bonding networks of PULL chains were disrupted after conjugation of PTX residues. 11 The distinctive crystalline signals of PTX were also vanished upon its grafting to the PULL backbone, suggesting that PTX was molecularly dispersed in the NPs. This result showed a good agreement with the DSC outcomes.…”

Section: Synthesis and Characterization Of Pull−cc−ptx And Pull−ss−ptxmentioning

confidence: 99%

See 2 more Smart Citations

Engineering Transferrin-Decorated Pullulan-Based Prodrug Nanoparticles for Redox Responsive Paclitaxel Delivery to Metastatic Lung Cancer Cells

Zhao

Guo

Bera

et al. 2023

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

Paclitaxel (PTX) remains a cornerstone in the treatment of locally advanced and metastatic lung cancer. To improve its therapeutic indices against lung cancer, novel redox-sensitive pullulan/PTX-based prodrug NPs (PULL–SS–PTX NPs) were accomplished, which were further surface-decorated with transferrin (TF), a cancer cell-targeting ligand, to afford TF–PULL–SS–PTX NPs. These prodrug NPs (drug content, >37% and average size, 134–163 nm) rapidly dismantled their self-assembled architecture upon exposure to simulated reducing conditions, causing a triggered drug release as compared to the control scaffold (PULL–CC–PTX NPs). These scaffolds also evidenced outstanding colloidal stability, cellular uptake efficiency, and discriminating cytotoxicity between the cancer and healthy cells. Intravenously delivered redox-sensitive NPs exhibited improved tumor-suppressing properties as compared to the control nanovesicles (PULL–CC–PTX NPs) in a B16–F10 melanoma lung metastasis mice model. The targeting efficiency and associated augmented anticancer potentials of TF–PULL–SS–PTX NPs relative to TF-free redox-responsive NPs and Taxol intravenous injection were also established on the transferrin receptor (TFR) overexpressed Lewis lung carcinoma (LLC–luc) cell-bearing mice model. Moreover, the TF-functionalized scaffold displayed a reduced systemic toxicity compared to that of Taxol intravenous injection. Overall, the proposed TF-decorated prodrug NPs could be a promising nanomedicine for intracellular PTX delivery against metastatic lung cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Synthesis and Characterization Of Pull−cc−ptx And Pull−ss−ptxmentioning

confidence: 99%

See 1 more Smart Citation

Engineering Transferrin-Decorated Pullulan-Based Prodrug Nanoparticles for Redox Responsive Paclitaxel Delivery to Metastatic Lung Cancer Cells

Zhao

Guo

Bera

et al. 2023

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

show abstract

“…Meanwhile, hypoxic microenvironment provides an opportunity for specific tumor inhibition by harnessing hypoxia-sensitive or activatable DDSs. For example, an Erlo-loaded hypoxia-sensitive polymeric nanomedicine showed accelerated drug release in hypoxic condition and better inhibition effect in drug-resistant hypoxic HeLa cells than pristine Erlo …”

Section: Egfr-tki-based Combinational Cancer Therapymentioning

confidence: 99%

“…For example, an Erlo-loaded hypoxia-sensitive polymeric nanomedicine showed accelerated drug release in hypoxic condition and better inhibition effect in drug-resistant hypoxic HeLa cells than pristine Erlo. 209 3.5.4.3. Macrophage Polarization.…”

Section: Photothermal Therapy (Ptt)mentioning

confidence: 99%

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy

Pan

et al. 2023

Mol. Pharmaceutics

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) plays a key role in signal transduction pathways associated with cell proliferation, growth, and survival. Its overexpression and aberrant activation in malignancy correlate with poor prognosis and short survival. Targeting inhibition of EGFR by small-molecular tyrosine kinase inhibitors (TKIs) is emerging as an important treatment model besides of chemotherapy, greatly reshaping the landscape of cancer therapy. However, they are still challenged by the offtargeted toxicity, relatively limited cancer types, and drug resistance after long-term therapy. In this review, we summarize the recent progress of oral, pulmonary, and injectable drug delivery systems for enhanced and targeting TKI delivery to tumors and reduced side effects. Importantly, EGFR-TKI-based combination therapies not only greatly broaden the applicable cancer types of EGFR-TKI but also significantly improve the anticancer effect. The mechanisms of TKI resistance are summarized, and current strategies to overcome TKI resistance as well as the application of TKI in reversing chemotherapy resistance are discussed. Finally, we provide a perspective on the future research of EGFR-TKI-based cancer therapy.

show abstract

A Review on Natural and Synthetic Polymers Used in the Preparation of Nanofibrous Scaffolds for Faster Wound Healing

Rajput,

Ghosh,

Kashyap

et al. 2024

Nanotechnology in the Life Sciences

View full text Add to dashboard Cite

Etherified pullulan-polyethylenimine based nanoscaffolds improved chemosensitivity of erlotinib on hypoxic cancer cells.

Cited by 8 publications

References 59 publications

Engineering Transferrin-Decorated Pullulan-Based Prodrug Nanoparticles for Redox Responsive Paclitaxel Delivery to Metastatic Lung Cancer Cells

Engineering Transferrin-Decorated Pullulan-Based Prodrug Nanoparticles for Redox Responsive Paclitaxel Delivery to Metastatic Lung Cancer Cells

Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy

A Review on Natural and Synthetic Polymers Used in the Preparation of Nanofibrous Scaffolds for Faster Wound Healing

Contact Info

Product

Resources

About